

## Product datasheet for **TL309683V**

### **RUNX2 Human shRNA Lentiviral Particle (Locus ID 860)**

#### **Product data:**

<b>Product Type:</b>	shRNA Lentiviral Particles
<b>Product Name:</b>	RUNX2 Human shRNA Lentiviral Particle (Locus ID 860)
<b>Locus ID:</b>	860
<b>Synonyms:</b>	AML3; CBF-alpha-1; CBFA1; CCD; CCD1; CLCD; OSF-2; OSF2; PEA2aA; PEBP2aA
<b>Vector:</b>	pGFP-C-shLenti (TR30023)
<b>Format:</b>	Lentiviral particles
<b>Components:</b>	RUNX2 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10 <sup>7</sup> TU/ml.
<b>RefSeq:</b>	<u><a href="#">NM_001015051</a></u> , <u><a href="#">NM_001024630</a></u> , <u><a href="#">NM_001278478</a></u> , <u><a href="#">NM_004348</a></u> , <u><a href="#">NR_103532</a></u> , <u><a href="#">NR_103533</a></u> , <u><a href="#">NM_001024630.1</a></u> , <u><a href="#">NM_001024630.2</a></u> , <u><a href="#">NM_001024630.3</a></u> , <u><a href="#">NM_001015051.1</a></u> , <u><a href="#">NM_001015051.2</a></u> , <u><a href="#">NM_001015051.3</a></u> , <u><a href="#">NM_004348.1</a></u> , <u><a href="#">NM_004348.2</a></u> , <u><a href="#">NM_004348.3</a></u> , <u><a href="#">NM_001278478.1</a></u> , <u><a href="#">BC108919</a></u> , <u><a href="#">BC108920</a></u> , <u><a href="#">BC160022</a></u> , <u><a href="#">NM_001369405</a></u> , <u><a href="#">NM_001278478.2</a></u>
<b>UniProt ID:</b>	<u><a href="#">Q13950</a></u>
<b>Summary:</b>	This gene is a member of the RUNX family of transcription factors and encodes a nuclear protein with an Runt DNA-binding domain. This protein is essential for osteoblastic differentiation and skeletal morphogenesis and acts as a scaffold for nucleic acids and regulatory factors involved in skeletal gene expression. The protein can bind DNA both as a monomer or, with more affinity, as a subunit of a heterodimeric complex. Two regions of potential trinucleotide repeat expansions are present in the N-terminal region of the encoded protein, and these and other mutations in this gene have been associated with the bone development disorder cleidocranial dysplasia (CCD). Transcript variants that encode different protein isoforms result from the use of alternate promoters as well as alternate splicing. [provided by RefSeq, Jul 2016]
<b>shRNA Design:</b>	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).